Circular RNA

Pioneering a New Era in Depression Diagnosis: Overcoming Skepticism with Science   Depression affects millions of people worldwide, yet its diagnosis remains largely subjective. Currently, most psychiatrists rely on depression rating scales—questionnaires that assess symptoms based on patient responses. While these tools are widely used, they leave room for interpretation and may not always capture the full biological complexity of depression.    Our company is changing that. We manufacture an in vitro diagnostic (IVD) product for depression—a groundbreaking innovation that provides an objective, Circular RNA biomarker-based approach to diagnosis. Despite the strong scientific backing of our products—supported by over 15 published research articles and more than 1,000 clinical trials—introducing this innovation to the market has been met with hesitation.    Facing Doubts in a Traditional Field When promoting our IVD products to hospitals, clinics, and distributors, the response is often cautious. Many medical professionals, accustomed to decades of subjective assessment tools, question the validity and necessity of a biological test for depression. Some common objections include:    Why do we need a diagnostic test when rating scales have worked for years? How do we know these biomarkers are reliable? Will insurance cover this? Will doctors adopt it?   These concerns are understandable. Change is difficult, especially in a field as complex as mental health. However, the resistance does not diminish the potential impact of our technology.    Standing Firm in Our Mission  Despite the skepticism, I remain unwavering in my commitment to bringing this innovation to the world. Every objection is an opportunity to educate—to demonstrate how our test can:  ✔ Improve diagnostic accuracy–Reducing misdiagnosis and ensuring patients receive the right treatment sooner.  ✔ Complement existing methods –Providing psychiatrists with additional data to make more informed decisions.  ✔ Reduce stigma – Reinforcing that depression is not just "in the mind" but has measurable biological components.    The Road Ahead Innovation is never easy. The greatest medical breakthroughs—from the discovery of antibiotics to the development of vaccines—faced initial resistance before becoming standard practice. Our journey is no different.  I will continue to engage with doctors, researchers, and healthcare providers, armed with data and real-world evidence. I will listen to their concerns, refine our approach, and persist in demonstrating the value of our IVD products.  Because at the heart of this mission are the millions of people suffering from depression—people who deserve faster, more accurate diagnoses and better treatment options. This is more than just a product. It’s a revolution in mental health care. And I won’t stop until the world sees its potential. 

Today's featured article: “Circular RNA in Schizophreniaand Depression” By Zexuan Li, Sha Liu, Xinrong Li, Wentao Zhao, Jing Li, and Yong Xu   Since circRNA is easily detected in peripheral blood and has a high degree of spatiotemporal tissue specificity and stability, these attributes provide us with a new idea to further explore the potential value for the diagnosis and treatment of Depression.   you can refer to the complete article through the link as below